Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Interim 75 patients Data might be good (Dec 14th Week)

<< Previous

Bullboard Posts

Next >>

Comment by Danorrnon Dec 07, 2020 5:57am

183 Views

Post# 32047905

RE:RE:Interim 75 patients Data might be good (Dec 14th Week)

To the qanon covidiot...I deal with this virus everyday. The virus also causes severe clotting. You do understand that we have blood vessels throughout our bodies? This means many organs including the heart and brain are at risk. You're so paranoid of the news media you're willing to follow any other news regardless of it being science based or not. The virus and its effects are real.

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity